Literature DB >> 33425160

[Administration of analgesics at home for the treatment of vaso-occlusive crises before admission to hospital].

Alima Yanda Anastasie Nicole1,2, Eposse Ekoube Charlotte3,4, Ngatsing Christelle Shanti2, Mandeng Ma Linwa Edgar5, Françoise Ngnedjou Nwabufor Foute6, Ngou Patrick7, Mbono Ritha4, Djike Puepi Yolande5, Epee Patricia4, Wete Estelle2, Koki Ndombo Paul Olivier2,7.   

Abstract

INTRODUCTION: vaso-occlusive crises (VOCs) are the primary reason for admission and hospitalization in children with sickle cell disease and most often they require home care before arriving to consultation. The purpose of this study was to describe home-based therapy for children with sickle cell disease admitted with VOCs.
METHODS: we conducted a descriptive and analytical cross-sectional study, in the pediatric emergencies at the Mother and Child Centre of the Chantal Biya Foundation (CBF) over a 4-month period from February to May 2018. Consecutive sampling was used. All patients with sickle cell disease presenting with VOCs were included in the study.
RESULTS: one hundred and fifty-two patients were enrolled. The most represented age group was 5- 10 years. Eighty-two patients (54%) presented more than 24 hours after the onset of the crises and 70 (46%) in the first 24 hours; 80% (n=122) of our sample had received analgesic treatment at home. Escalation of therapy was found in 31.2% of cases. The use of prescription medications (75.4%, n=92) was dominant as the 1st recourse. The dosage for analgesics was not correct in 67% of cases (overdose in 70% of cases). The correct dosage of home-based analgesics was administered in only 33% of patients.
CONCLUSION: this study shows that home-based management of VOCs is inadequate. Measures must be taken to ensure that all patients with sickle cell disease can effectively manage minor to moderate VOCs at home. Copyright: Alima Yanda Anastasie Nicole et al.

Entities:  

Keywords:  Treatment; analgesic; vaso-occlusive crises

Mesh:

Substances:

Year:  2020        PMID: 33425160      PMCID: PMC7755375          DOI: 10.11604/pamj.2020.37.127.25062

Source DB:  PubMed          Journal:  Pan Afr Med J


  8 in total

1.  [Study of access to health care and drugs in Cameroon: 1. Methods and validation].

Authors:  Christophe Commeyras; Jean Rolin Ndo; Omar Merabet; Hamidou Koné; Faraniaina Patricia Rakotondrabé
Journal:  Sante       Date:  2005 Jul-Sep

2.  Health-related quality of life in children and adolescents with sickle cell disease.

Authors:  Juanita Conkin Dale; Cindy J Cochran; Lonnie Roy; Ethel Jernigan; George R Buchanan
Journal:  J Pediatr Health Care       Date:  2010-04-02       Impact factor: 1.812

Review 3.  Psychological complications in sickle cell disease.

Authors:  Kofi A Anie
Journal:  Br J Haematol       Date:  2005-06       Impact factor: 6.998

4.  [Home care of vaso-occlusive crisis in sickle cell disease in Togo].

Authors:  A D Gbadoé; D Y Atakouma; A Akoli; J K Assimadi
Journal:  Arch Pediatr       Date:  1999-09       Impact factor: 1.180

5.  [Sickle Cell Disease International Organization (SCDIO)].

Authors:  E Ebakisse-Badassou
Journal:  Med Trop (Mars)       Date:  2010-12

6.  Home management of sickle cell-related pain in children and adolescents: natural history and impact on school attendance.

Authors:  Barbara S Shapiro; David F Dinges; Emily Carota Orne; Nancy Bauer; Linnette B Reilly; Wayne G Whitehouse; Kwaku Ohene-Frempong; Martin T Orne
Journal:  Pain       Date:  1995-04       Impact factor: 6.961

7.  Characteristics of pain managed at home in children and adolescents with sickle cell disease by using diary self-reports.

Authors:  Carlton Dampier; Beth Ely; Darcy Brodecki; Patricia O'Neal
Journal:  J Pain       Date:  2002-12       Impact factor: 5.820

8.  [Psychosocial impact of sickle cell disease in the parents of children living in Kinshasa, Democratic Republic of Congo: a qualitative study].

Authors:  Evariste Luboya; Jean-Christophe Bukasa Tshilonda; Mathilde Bothale Ekila; Michel Ntetani Aloni
Journal:  Pan Afr Med J       Date:  2014-09-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.